NCT03903185View on ClinicalTrials.gov

Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

July 1, 2023

Study Completion Date

August 15, 2023

Conditions
Hepatitis C, ChronicHematologic Malignancy
Interventions
DRUG

Ledipasvir / Sofosbuvir Oral Product

45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food

Trial Locations (2)

11556

Pediatric Hematology Oncology and BMT Department, Faculty of Medicine, Ain Shams University, Cairo

11566

Faculty of Medicine Ain Shams Research Institute- Clinical Research Center (MASRI-CRC), Cairo

All Listed Sponsors
collaborator

Cairo University

OTHER

lead

Ain Shams University

OTHER

NCT03903185 - Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy | Biotech Hunter | Biotech Hunter